Cancer Probe Biotech Secures RMB 100 Million Series B Funding to Accelerate Pre-STAR Market Filing and Expand Oncology Early Detection Pipeline

On July 6, Hangzhou Capol Biotechnology Co., Ltd. announced the completion of its RMB 100 million Series B financing round. The proceeds from this round will be used to accelerate the advancement of its R&D pipeline and facilitate its pre-registration listing on the STAR Market.

Guo Yongliang, Chairman of Huaxia Hengtian Capital; Wang Yaohui, Managing Director of BOCI; Shao Xiangrong, Dean of the Hangzhou Branch of the Zhejiang Tsinghua Yangtze Delta Research Institute; Li Xiaofeng, Deputy Dean of the Hangzhou Branch of the Zhejiang Tsinghua Yangtze Delta Research Institute; Zhao Nanming, Academician of the International Eurasian Academy of Sciences and former Dean of the School of Life Sciences and Engineering at Tsinghua University; and Sun Supeng, Founder and CEO of Hangzhou Capol Biotech Co., Ltd., jointly kicked off the signing ceremony for the Series B financing round in Binjiang, Hangzhou.

Kaipaulo Bio originated from Tsinghua University, with its R&D founding team comprising a “mentor-mentee” duo from the Department of Biology at Tsinghua University. Professor Zhao Nanming is the former Dean of the Institute of Life Sciences and Engineering at Tsinghua University. Dr. Kevin Sun, who earned his undergraduate degree in Biology from Tsinghua University, subsequently studied under two Nobel Laureates and brings nearly 25 years of global biological R&D experience from top-tier U.S. biomedical institutions such as the UT Southwestern Medical Center and globally renowned pharmaceutical companies. In early 2013, Professor Zhao Nanming, Dr. Kevin Sun, and Sun Supeng, an MBA graduate from the National School of Development at Peking University, jointly founded Kaipaulo Bio in Hangzhou, Zhejiang Province.

“Two Tsinghua Biology Scientists and One Peking University MBA”: The three founders, diligent, pragmatic, and understated, have dedicated themselves for eight years to breakthroughs in blood-based cancer screening technology. In 2015, one of their core products, the “Seven Autoantibodies for Lung Cancer” assay, was successfully launched as the first kit approved by the National Medical Products Administration (NMPA) for blood-based detection of pulmonary nodules and early-stage lung cancer, transforming China’s traditional “single-dimensional CT imaging” model for lung cancer screening. By identifying high-risk populations through molecular biomarkers such as lung cancer serum autoantibodies, this approach enables precise screening, reduces costs, and improves efficiency and yield. Furthermore, it facilitates risk stratification and follow-up management of small pulmonary nodules using lung cancer serum autoantibodies, establishing a precision lung cancer screening strategy and pathway tailored to China’s specific conditions. In 2019, Capollo’s core technology was awarded the Second Prize of the State Scientific and Technological Progress Award as a “Key Technology for Precision Diagnosis and Treatment of Lung Cancer.”

“Self-discipline and Social Commitment” is the motto of Tsinghua University, as well as the core of Capollo’s corporate culture and business philosophy. As a leading enterprise in the field of early lung cancer screening in China, Capollo has not adopted a business model driven by multiple rounds of financing, scale expansion, or rapid growth. Instead, adhering to the strategy of “self-improvement,” Capollo has focused on strengthening its internal R&D capabilities, withstood pressures, and systematically addressed pricing and medical insurance reimbursement barriers across 30 provinces in China, while repeatedly refining its business model in local markets. By 2020, Capollo had obtained pricing approvals in more than 20 provinces, including Beijing, Shanghai, Guangdong, Jiangsu, and Zhejiang, with some provinces already incorporating its services into medical insurance coverage. This achievement made Capollo the fastest-growing novel precision oncology company in China’s precision medicine sector in terms of pricing progress. Its services covered over 300 top-tier hospitals nationwide, and the company achieved overall profitability even during the pandemic.

The 20th World Conference on Lung Cancer (WCLC) was held in Barcelona, Spain, from September 7 to 10, 2019. At the plenary session, results from the world’s largest blood-based screening study for lung cancer were announced, garnering widespread recognition from the global lung cancer community for lung cancer screening technology based on autoantibodies against tumor-associated antigens. During the official press conference of the WCLC, these milestone findings were prominently presented to a global audience, with a call to advance the clinical application of autoantibody-based technologies—leveraging tumor immune responses—for early screening and diagnosis of lung cancer worldwide. To date, this autoantibody-based immunological approach remains the only technology validated by evidence-based medicine to demonstrate benefits in large-scale blood-based lung cancer screening.

Since 2013, the R&D team at Capollo has been independently developing early detection biomarkers for various solid tumors in the field of tumor immunology. Leveraging its convenient and rapid testing method, the lung cancer serum antibody test has filled a gap in the market for blood-based early detection of lung cancer and addressed the limitations of CT scans in screening for central-type lung cancer. Upon its launch, it quickly gained market recognition and has been widely adopted by major public Grade A tertiary hospitals across China. This technology has also been strongly endorsed by nearly one hundred leading experts in the country. In 2019, it was included in the “Chinese Expert Consensus on Lung Cancer Screening and Management” and the “Chinese Expert Consensus on Early Diagnosis of Lung Cancer,” becoming an officially recommended blood test for pulmonary nodules and an opportunistic screening tool for lung cancer in China.

Guo Yongliang, Chairman of Huaxia Hengtian Capital, stated“The clinical need for early screening and diagnosis of tumors is clear and highly significant. Capollo holds a leading position in the lung cancer screening industry, with boundless future prospects. We believe that through our collaboration and the joint efforts of shareholders and the company’s team, Capollo will soon grow into an enterprise that delivers substantial value to human health and becomes a source of pride.”

BOCI Managing Director Wang Yaohui stated“Kaipaoluo is a company that can bring the true gospel of health to millions of people. With the successive introduction of the registration-based IPO systems on China’s STAR Market and ChiNext, the company is bound to attract greater social attention and market enthusiasm after its listing. In the future, Kaipaoluo may grow into an enterprise with a scale of hundreds of billions of yuan, becoming a landmark company in China’s healthcare industry.”

Dean Shao Xiangrong of the Hangzhou Branch of the Yangtze Delta Region Institute of Tsinghua University stated“Capollo Bio, originating from Tsinghua University, is a high-quality project incubated by the Yangtze Delta Region Institute of Tsinghua University in Zhejiang. Currently, Capollo’s core technologies and products have received national recognition. More excitingly, multiple products under development have made encouraging progress and are expected to obtain relevant product registration certificates next year. At that time, Capollo Bio will achieve a qualitative leap. This progress would not have been possible without the help, support, and empowerment of both new and existing shareholders. Shareholders should continue to add value and multiply opportunities for the enterprise, jointly fueling the company’s ascent and working hand in hand to promote its healthy and rapid development.”

Sun Supeng, Founder and CEO of Kaipaolo Biotech, stated“Warmly welcome Huaxia Hengtian Capital to join the Capollo team. Upon completion of this financing round, the Company will further increase its R&D investment to accelerate the registration and market launch of over a dozen solid tumor products, including blood-based screening tests for breast cancer and esophageal cancer. The 2019 Government Work Report pointed out that tens of millions of families in China are affected by cancer, and the state shall implement cancer prevention and control initiatives, promote preventive screening, early diagnosis and early treatment, and tackle key scientific and technological challenges, with a focus on alleviating critical livelihood issues. The entire Capollo team will continue to strive for excellence, taking the promotion of early cancer screening and diagnosis in China as its corporate mission, and fully contributing to the ‘Healthy China 2030’ initiative!”

Kaipu Luo Biotech is a cancer early-screening biotechnology enterprise with global R&D competitiveness, originating from Tsinghua University, and is the first biotechnology company in China to receive the National Science and Technology Progress Award in the field of cancer screening.

The company boasts a world-class R&D team. Professor Zhao Nanming, one of the founders and former Dean of the Institute for Life Sciences and Engineering at Tsinghua University, established Tsinghua’s Department of Biological Sciences and mentored a cohort of globally leading biological scientists, including Shi Yigong. Another founder, Professor Kevin Sun, a graduate of Tsinghua’s Department of Biological Sciences, studied under two Nobel laureates and brings nearly 25 years of global biopharmaceutical R&D experience from top-tier U.S. institutions such as the University of Texas Southwestern Medical Center and the globally renowned pharmaceutical company Merck & Co. The R&D capabilities of the founding team represent the pinnacle of biological research and development in both China and worldwide.

The company boasts a robust R&D pipeline, with over a dozen early-detection development projects for solid tumors, including blood-based tests for early-stage breast cancer, which have the potential to reshape the global landscape of cancer prevention and screening for breast cancer and other malignancies.

The 2019 Government Work Report pointed out that tens of millions of families in China are affected by cancer, and it is necessary to implement cancer prevention and control actions, promote preventive screening, early diagnosis and treatment, and key scientific research, focusing on alleviating the pain points of people's livelihood. Kaipaulo Company has been striving to make progress, taking the promotion of early screening and diagnosis of cancer in China as the company's mission, and fully promoting Healthy China 2030!